Journal of Clinical Endocrinology & Metabolism, Vol 70, 1103-1107, Copyright © 1990 by Endocrine Society

ARTICLES

Brain natriuretic peptide administered to man: actions and metabolism

A McGregor, M Richards, E Espiner, T Yandle and H Ikram
Department of Endocrinology, Princess Margaret Hospital, Christchurch, New Zealand.

To investigate the effects and metabolism of brain natriuretic peptide (BNP) in man, eight normal subjects received 3-h infusions of synthetic porcine BNP (2 pmol/kg.min) in a placebo-controlled study. The MCR and plasma half-life of BNP were 2.69 L/min and 3.1 min, respectively. BNP clearly suppressed PRA to less than 50% of placebo values (P less than 0.001). Plasma aldosterone concentrations were also significantly reduced by 30% (P less than 0.05). Urinary sodium excretion tended to rise (P = 0.054), and urinary cGMP excretion was clearly enhanced (P less than 0.01). Systemic and renal hemodynamics, hematocrit, plasma protein concentrations, plasma ACTH, arginine vasopressin, PRL, and catecholamines were unchanged. Porcine BNP has a similar range of effects and is similarly metabolized in man as human ANP. Further elucidation of the possible role of BNP as a circulating hormone in man awaits measurement of tissue and plasma concentrations of human BNP in health and disease and provision of fuller dose-response data for human as well as porcine BNP.

This article has been cited by other articles:

				D. C. Kurian, I. J. Wagner, and M. Klapholz Nesiritide in Pulmonary Hypertension Chest, July 1, 2004; 126(1): 302 - 305. [Abstract] [Full Text] [PDF]

				M.R Cowie, P Jourdain, A Maisel, U Dahlstrom, F Follath, R Isnard, A Luchner, T McDonagh, J Mair, M Nieminen, et al. Clinical applications of B-type natriuretic peptide (BNP) testing Eur. Heart J., October 1, 2003; 24(19): 1710 - 1718. [Abstract] [Full Text] [PDF]

				K. van der Zander, A. J.H.M. Houben, A. A. Kroon, T. K.A. Wierema, M. J.M.J. Fuss-Lejeune, D. Koster, and P. W. de Leeuw Does Brain Natriuretic Peptide Have a Direct Renal Effect in Human Hypertensives? Hypertension, January 1, 2003; 41(1): 119 - 123. [Abstract] [Full Text] [PDF]

				D. L. Vesely, G. I. San Miguel, I. Hassan, and D. D. Schocken Atrial Natriuretic Hormone, Vessel Dilator, Long-Acting Natriuretic Hormone, and Kaliuretic Hormone Decrease the Circulating Concentrations of CRH, Corticotropin, and Cortisol J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4244 - 4249. [Abstract] [Full Text] [PDF]

				K. van der Zander, A. J.H.M Houben, A. A Kroon, and P. W de Leeuw Effects of brain natriuretic peptide on forearm vasculature: comparison with atrial natriuretic peptide Cardiovasc Res, December 1, 1999; 44(3): 595 - 600. [Abstract] [Full Text] [PDF]

				R. M. Mills, T. H. LeJemtel, D. P. Horton, C.-s. Liang, R. Lang, M. A. Silver, C. Lui, K. Chatterjee, and on Behalf of the Natrecor Study Group Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: A randomized, double-blind, placebo-controlled clinical trial J. Am. Coll. Cardiol., July 1, 1999; 34(1): 155 - 162. [Abstract] [Full Text] [PDF]

				Y. Yano, A. Katsuki, E. C. Gabazza, K. Ito, M. Fujii, M. Furuta, K. Tuchihashi, H. Goto, K. Nakatani, Y. Hori, et al. Plasma Brain Natriuretic Peptide Levels in Normotensive Noninsulin-Dependent Diabetic Patients with Microalbuminuria J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2353 - 2356. [Abstract] [Full Text]

				R. L. Woods and M. J. M. Jones Atrial, B-type, and C-type natriuretic peptides cause mesenteric vasoconstriction in conscious dogs Am J Physiol Regulatory Integrative Comp Physiol, May 1, 1999; 276(5): R1443 - R1452. [Abstract] [Full Text] [PDF]

				G. Barletta, C. Lazzeri, S. Vecchiarino, R. Del Bene, G. Messeri, A. Dello Sbarba, M. Mannelli, and G. La Villa Low-Dose C-Type Natriuretic Peptide Does Not Affect Cardiac and Renal Function in Humans Hypertension, March 1, 1998; 31(3): 802 - 808. [Abstract] [Full Text] [PDF]

				G. B. Pidgeon, A. M. Richards, M. G. Nicholls, E. A. Espiner, T. G. Yandle, and C. Frampton Differing Metabolism and Bioactivity of Atrial and Brain Natriuretic Peptides in Essential Hypertension Hypertension, April 1, 1996; 27(4): 906 - 913. [Abstract] [Full Text]

				G. La Villa, G. Bisi, C. Lazzeri, C. Fronzaroli, L. Stefani, G. Barletta, R. Del Bene, G. Messeri, G. Strazzulla, and F. Franchi Cardiovascular Effects of Brain Natriuretic Peptide in Essential Hypertension Hypertension, May 1, 1995; 25(5): 1053 - 1057. [Abstract] [Full Text]

				K. Koller, D. Lowe, G. Bennett, N Minamino, K Kangawa, H Matsuo, and D. Goeddel Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP) Science, April 5, 1991; 252(5002): 120 - 123. [Abstract] [PDF]